ABSI — Absci Corp
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1672688 ·
Last close
$9.49
Market Cap
$1.63B
52W High
$12.06
52W Low
$2.24
ADV30
3,501,687
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 318,000 | — | -34,158,000 | -33,210,000 | 268,917,000 | 107,865,000 | 22,786,000 |
| Mar 2026 | 215,000 | — | -30,846,000 | -29,599,000 | 195,593,000 | 8,627,000 | 23,622,000 |
| Dec 2025 | 650,000 | — | -36,142,000 | -29,562,000 | 216,297,000 | 20,025,000 | 26,848,000 |
| Sep 2025 | 378,000 | — | -30,154,000 | -28,706,000 | 244,992,000 | 9,476,000 | 34,652,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-97,393,000
Investing CF
$-27,754,000
Financing CF
$70,711,000
CapEx
$-1,240,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-654,383,000
Inventory
—
Receivables
$1,000,000
ST Investments
$117,078,000
EBIT TTM
$-118,197,000
Pretax Income TTM
$-118,345,000
Interest Exp TTM
$148,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,561,000
EBITDA
$-119,506,000
Free Cash Flow
$-50,591,752
Enterprise Value
$1,211,638,016
Total Cash
$201,142,000
Total Debt
$3,829,000
Shares Out
171,614,010
Trailing EPS
$-0.79
Book Value
$1.44
ROE
-57.7%
ROA
-34.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,800,000 | -125,418,000 | -115,183,000 | 216,297,000 | 26,848,000 | 189,449,000 | -92,925,000 |
| Dec 2024 | 4,534,000 | -108,888,000 | -103,106,000 | 213,608,000 | 34,475,000 | 179,133,000 | -72,402,000 |
| Dec 2023 | 5,718,000 | -94,180,000 | -110,566,000 | 217,298,000 | 41,122,000 | 176,176,000 | -64,636,000 |
| Dec 2022 | 5,747,000 | -106,750,000 | -104,904,000 | 321,008,000 | 46,594,000 | 274,414,000 | -81,339,000 |
TTM Snapshot
Revenues TTM
$2,880,000
NetIncome TTM
$-53,744,000
OpCashFlow TTM
$0
Assets (Latest)
$216,297,000
Forward EPS
$-0.68
Max Pain — expiry 2026-10-16
max pain strike: $10.00 · spot: $9.49 · call oi: 6,868 · put oi: 2,777
Expected Move to 2026-10-16:
±$1.50
(15.81%) —
implied range
$7.99 –
$10.99
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | $1.60B | $11.42 | — |
| CLDX | Celldex Therapeutics, Inc. | $2.47B | $31.49 | — |
| NEOG | NEOGEN CORP | $2.99B | $13.72 | — |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $797.49M | $7.75 | — |
| QDEL | QuidelOrtho Corp | $742.67M | $10.83 | — |
News headlines (Yahoo Finance, 1h cache)
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
2026-09-24 12:00 · Yahoo
Absci (ABSI) Stock Looks Expensive Against Its Book Value
2026-09-22 08:19 · Yahoo
Absci to Participate in Upcoming Investor Conferences
2026-09-01 12:00 · Yahoo
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
2026-08-18 07:43 · Yahoo
Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation
2026-08-12 17:11 · Yahoo
Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?
2026-08-12 07:10 · Yahoo
Absci Q2 Earnings Call Highlights
2026-08-11 22:04 · Yahoo
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
2026-08-11 20:05 · Yahoo
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
2026-09-21 01:02 · Yahoo
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
2026-09-12 00:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.